PUBLIC HEALTH GRAND ROUNDS: A New Public Health Order in the 21st Century

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email
Share on print

COVID-19 Vaccine Manufacturing in Africa: Research & Development, Hubs and Talent Development

Currently, Africa has low capability to manufacture vaccines: less than 1% of Africa’s routine vaccines are locally manufactured, and production is mostly concentrated in 5 countries (South Africa, Morocco, Tunisia, Egypt and Senegal). This has led to over- reliance on global supply; as such, exposing Africans to supply chain risks such as the one experienced with the current COVID-19 vaccine challenges.

There have been a number of actions to expand Africa’s pharmaceutical manufacturing capability. In 2007, the African Union Heads of State and Government, endorsed the Pharmaceutical Manufacturing Plan for Africa (PMPA) with the aim of strengthening Africa’s manufacturing ability to contribute to improved health outcomes and realize economic benefits.
The PMPA recommended approaches to enable Member States to build local manufacturing capability of pharmaceuticals. Moreover, the World Trade Organization’s (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement offers flexibilities through which Members States can either build manufacturing capability or access affordable medical products. However, there are barriers that countries need to overcome to enable them to properly utilize and implement these recommendations and flexibilities: weak regulatory environments; procurement challenges; restricted access to finance; limited local skills; and a lack of clear co-ordination among Member States and sectors.

Date

14 October 2021 – 14 October 2021

Organiser

Africa CDC

Venue

Zoom

Language

English, French

TRANSLATE THIS PAGE >
Scroll to Top